இம்யூனோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from இம்யூனோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In இம்யூனோ Today - Breaking & Trending Today
CHICAGO, April 22, 2021 /PRNewswire/ According to the new market research report "Immuno Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR ....
(0) CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021(NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised its option to develop an additional bispecific program under the ongoing collaboration with F-star. This is the third option to license a preclinical program that Merck KGaA, Darmstadt, Germany has exercised in the ongoing collaboration with F-star. Merck KGaA, Darmstadt, Germany and F-star originally entered into a collaboration agreement in 2019 with the first option to license. In July 2020, Merck KGaA, Darmstadt, Germany brought the second program from the collaboration into its pipeline, and today has exercised its third option, taking over future development and commercialization of the program. An undisclosed option exercise paymen ....
OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual Meeting Permanent Abstract Number: 1636 Title: Optimized antagonist anti-PD-1/IL-7 mutein bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Morello A., Seité M., Durand J, Thépenier V., Teppaz G., Pengam S., Wilhelm E., Desselle A., Girault I., Mary C., Poirier N. Session Type: E-Poster Session Session Title: Therapeutic Antibodies Title: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis Gauttier V., Lavy M., Trilleaud C., Biteau K., Girault I., Belarif L., Teppaz G., Mary C., Thepenier V., Blanquart C., Barillé-Nion S., Poirier N. ....
NEW YORK CITY (dpa-AFX) - Genome and Company said that it has expanded collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric ....
Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that members of Transgene s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences: ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4: Éric Quéméneur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session Where next with Oncolytics about Date Time: March 3 rd at 4.20pm (CET) Royal Society Meeting on Immuno-oncology: How to get the immune system to beat cancer which will take place March 24-25: ....